UNSPSC 51434202: Deserpidine

This classification denotes an antihypertensive agent with the molecular formula C32H38N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9016E3VB47, chemically known as 3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) but generally known as deserpidine, which bears US NIH Compound Identifier 8550. European Medicines Agency schedules Deserpidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06992MIG.

UNSPSC 51434202 Deserpidine is a Commodity code covering pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing initiatives. Recent solicitations show state and local agencies buying advanced life support medications, generic pharmaceuticals, and over-the-counter products through formal competitive bidding and cooperative purchasing agreements. The City of Tampa and the Texas Health and Human Services Commission represent typical issuing bodies — municipalities operating emergency services and state health agencies managing pharmacy benefit programs — alongside multistate cooperative purchasing alliances that aggregate demand across state and local jurisdictions.

Activity under the code spans Florida, Texas, and the multistate cooperative purchasing network anchored in Minnesota. The City of Tampa's Purchasing Department solicited sealed bids (IFB No. 26P00188, due April 8, 2026) for Advanced Life Support Medications to supply Tampa Fire Rescue, with four specific medication line items totaling an estimated contract value of $40,000.00 and a one-year term with two one-year renewal options. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, response due April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026, and participation extending to Oregon and other member jurisdictions. MMCAP imposed a 3 percent administrative fee and required vendors to maintain insurance including $5,000,000 commercial general liability coverage. Tampa's solicitation included a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount, not to exceed $10,000.